Your browser doesn't support javascript.
Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.
Levin, Seth N; Venkatesh, Shruthi; Nelson, Katie E; Li, Yi; Aguerre, Ines; Zhu, Wen; Masown, Karman; Rimmer, Kathryn T; Diaconu, Claudiu I; Onomichi, Kaho B; Leavitt, Victoria M; Levine, Libby L; Strauss-Farber, Rebecca; Vargas, Wendy S; Banwell, Brenda; Bar-Or, Amit; Berger, Joseph R; Goodman, Andrew D; Longbrake, Erin E; Oh, Jiwon; Weinstock-Guttman, Bianca; Thakur, Kiran T; Edwards, Keith R; Riley, Claire S; Xia, Zongqi; De Jager, Philip L.
  • Levin SN; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Venkatesh S; New York Presbyterian Hospital, New York, New York, USA.
  • Nelson KE; Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Li Y; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Aguerre I; Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Zhu W; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Masown K; Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Rimmer KT; Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Diaconu CI; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Onomichi KB; New York Presbyterian Hospital, New York, New York, USA.
  • Leavitt VM; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Levine LL; New York Presbyterian Hospital, New York, New York, USA.
  • Strauss-Farber R; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Vargas WS; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Banwell B; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Bar-Or A; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Berger JR; Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
  • Goodman AD; New York Presbyterian Hospital, New York, New York, USA.
  • Longbrake EE; Department of Neurology, Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Oh J; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Weinstock-Guttman B; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Thakur KT; Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, New York, USA.
  • Edwards KR; Department of Neurology, Yale University, New Haven, Connecticut, USA.
  • Riley CS; Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Xia Z; Department of Neurology, Jacobs Multiple Sclerosis Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.
  • De Jager PL; New York Presbyterian Hospital, New York, New York, USA.
Ann Clin Transl Neurol ; 8(4): 918-928, 2021 04.
Article in English | MEDLINE | ID: covidwho-1092494
ABSTRACT

OBJECTIVE:

To report initial results of a planned multicenter year-long prospective study examining the risk and impact of COVID-19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS).

METHODS:

In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID-19 in persons with NID (PwNID) and change in their neurological care.

RESULTS:

Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID-19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID-19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID-19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID-19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID-19 (ORadj  = 1.45, 1.17-1.84). INTERPRETATIONS Our study of real-time, patient-reported experience during the COVID-19 pandemic complements physician-reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID-19 similar to the reference population.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases of the Nervous System / Self Report / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Qualitative research Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Ann Clin Transl Neurol Year: 2021 Document Type: Article Affiliation country: Acn3.51314

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases of the Nervous System / Self Report / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Qualitative research Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Ann Clin Transl Neurol Year: 2021 Document Type: Article Affiliation country: Acn3.51314